Last reviewed · How we verify
s-LMWH
At a glance
| Generic name | s-LMWH |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin (PHASE3)
- Informative Video Before LMWH Postpartum - Randomized Controlled Trial (NA)
- Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis (PHASE2, PHASE3)
- Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency (PHASE2)
- Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism (PHASE4)
- Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- s-LMWH CI brief — competitive landscape report
- s-LMWH updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI